mTOR in Different Tumor Types

Abnormally Activated mTOR May Play a Role in Many Cancers

Mutations in a number of cellular proteins and pathways located upstream from mTOR have been implicated in the development and spread of many types of cancer.1-15

These mutations include:

These mutations and others result in the abnormal activation of mTOR, which may lead to deregulated cell proliferation, tumor angiogenesis, and abnormal cell metabolism.

A more complete list of mutations that may abnormally activate mTOR
Selected mutations that may abnormally activate mTOR in cancer

Abnormally activated mTOR may play a role in a wide range of cancers, including renal cell carcinoma, lung cancer, breast cancer, colorectal cancer, and neuroendocrine tumors (NET). Inhibitors of mTOR are currently being evaluated in clinical trials in a number of different tumor types.

A more complete list of cancers in which mTOR may play a role.
mTOR is abnormally activated in many cancers

References:

  1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
  2. Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006;66:2028-2037.
  3. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000;2:335-344.
  4. Duran I, Salazar R, Casanovas O, et al. New drug development in digestive neuroendocrine tumors. Annals Oncol. 2007;18:1307-1313.
  5. Schips L, Ziguener R, Ratschek M, Rehak P, Ruschoff J, Langner C. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol. 2004;122:931-937.
  6. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954-2963.
  7. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221-1224.
  8. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res. 2003;63:7652-7656.
  9. Bjornsson J, Short MP, Kwiatkowski DJ, Petri Henske E. Tuberous sclerosis-associated renal cell carcinoma. Am J Pathol. 1996;149:1201-1208.
  10. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, et al. Eur J Pediatr. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. 1999;158:284-287.
  11. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002;62:3659-3662.
  12. Trojan J, Brieger A, Raedle J, Esteller M, Zeuzem S. 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. Gut. 2000;47:272-276.
  13. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta. 2005;1756:127-144.
  14. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005;65:2047-2053
  15. Gomella LG, Sargent ER, Wade TP, Anglard P, Marston Linehan W, Kasid A. Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β1 in renal cell carcinoma. Cancer Res. 1989;49:6972-6975.
  16. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
  17. Cunningham D, Humblet Y, Siena, S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
  18. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
  19. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101-115.
  20. Hankinson SE, Willet WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 1998;351:1393-1396.
  21. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-566.
  22. Minuto F, Del Monte P, Barreca A, et al. Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors. Cancer Res. 1986;46:985-988.
  23. Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie. 1999;81:403-407.
  24. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-I receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43:1-8.
  25. Burrow S, Andrulis I, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1 and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21-27.
  26. Bos JL. ras Oncongenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
  27. Samuels Y, Wang Z, Bardelli A. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
  28. Levine DA, Bogomolniy F, Yee CJ. et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875-2878.
  29. Itoh N, Semba S, Ito M, Tekeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumour progression in human colorectal carcinoma. Cancer. 2002;94:3127-3134.
  30. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779-6788.
  31. Mandal M, Kim S, Younes MN, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer. 2005;92:1899-1905.
  32. David O, Jett, J, LeBeau H, et al. Phospho—Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004;10:6865-6871.
  33. Dai D, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23:1473-1482.
  34. Lim J, Kim JH, Paeng JY, et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol. 2005;58:1199-1205.
  35. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178-1184.
  36. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
  37. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
Register
for mTOR Insights and receive the latest information on mTOR
E-mail this page
Print this page
Change font sizes